Corcept Therapeutics (CORT) Financials

$112.79

$-2.13 (-1.85%)

As on 11-Sep-2026 16:27EDT

Market cap

$12,066 Mln

Revenue (TTM)

$831 Mln

P/E Ratio

248

P/B Ratio

17.3

Div. Yield

0 %

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Operating Revenue	830.81	761.41	675.04	482.38	401.86	365.98
Cost of Revenue	14.09	12.98	10.88	6.48	5.39	5.28
Gross Profit	816.73	748.43	664.16	475.89	396.47	360.70
Operating Expenses	810.32	703.63	527.21	368.61	283.84	236.22
Operating Profit (EBIT)	6.41	44.80	136.95	107.28	112.63	124.48
Other Income	--	--	--	--	--	0.53
Profit before Tax	26.37	66.46	161.49	124.56	116.19	125.01
Provision for Tax	-35.26	-33.19	20.28	18.42	14.77	12.49
Profit after Tax (Net Income)	54.90	99.65	139.73	106.14	101.42	112.51
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	101.29	112.51

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Shareholder's Funds	705.78	647.81	679.59	506.71	501.84	375.81
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	29.12	22.76	20.19	10.31	9.10	0.41
Current Liabilities	153.80	166.09	140.77	104.51	72.49	47.54
Total Liabilities	1,042.50	836.65	840.55	621.52	583.43	423.76

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Non-Current Assets	449.03	351.19	368.95	162.88	84.18	157.29
Current Assets	439.68	485.46	471.60	458.64	499.25	266.46
Total Assets	1,042.50	836.65	840.55	621.52	583.43	423.76
Total Debt*	9.42	6.11	6.94	0.15	1.14	0.53
Net Current Assets	285.87	319.38	330.83	354.13	426.76	218.92

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Cash From Operating Activities	--	142.00	198.07	127.04	120.32	167.89
Cash Flow from Investing Activities	--	69.76	-177.60	90.91	-114.33	136.13
Cash from Financing Activities	--	-220.37	-28.35	-148.72	-17.28	-302.59
Net Cash Inflow / Outflow	--	--	--	--	--	1.43

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Adjusted EPS ($)	0.42	0.83	1.18	0.96	0.87	0.92
Cash EPS ($)	--	0.85	1.19	0.98	0.90	0.94
Adjusted Book Value ($)	--	5.40	5.74	4.57	4.31	3.07
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	1.18	1.67	1.15	1.03	1.37
Free Cash Flow per Share ($)	--	1.18	1.65	1.14	1.03	1.37

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
ROCE (%)	--	14.87	23.42	21.02	23.07	24.94
ROE (%)	8.11	15.01	23.56	21.05	23.11	25.03
ROA (%)	5.52	11.88	19.11	17.62	20.14	22.60
EBIT Margin (%)	3.17	8.73	23.92	25.82	28.03	34.01
Net Margin (%)	6.61	13.09	20.70	22.00	25.24	30.70
Cash Profit Margin (%)	0.00	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Revenue Growth (%)	16.02	0.13	0.40	0.20	0.10	0.03
EBIT Growth (%)	-79.11	-58.84	29.65	10.59	-9.51	-2.91
Net Profit Growth (%)	-58.66	-28.68	31.65	4.66	-9.86	6.13
EPS Growth (%)	-62.44	-0.30	0.23	0.10	-0.05	0.10
Book Value Growth (%)	12.98	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Price / Earnings	248.04	41.86	42.72	33.93	23.30	21.55
Price / Book Value	17.29	6.44	8.78	7.11	4.71	6.45
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	1,349.19	55.67	34.35	25.74	16.71	17.26
Close Price ($)	86.95	34.80	50.39	32.48	20.31	19.80
High Price ($)	91.00	117.33	61.66	34.28	30.14	31.18
Low Price ($)	28.66	32.99	20.84	17.86	16.47	15.83
Market Cap ($ Cr)	12,065.94	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Debt to Equity	--	0.01	0.01	0.00	0.00	0.00
Short term debt to equity ratio	0.00	0.00	0.00	0.00	0.00	0.00
Current Ratio	2.86	2.92	3.35	4.39	6.89	5.60
Quick Ratio	2.77	2.85	3.26	4.31	6.80	5.50
Interest Coverage	--	--	--	--	31.67	34.62

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21
Debtors to sales (%)	9.26	7.85	8.60	11.78	11.66	7.93
Asset Turnover	0.84	0.91	0.92	0.80	0.80	0.74
Receivable days	--	28.27	31.08	39.25	34.48	27.56
Inventory Days	--	355.76	338.03	389.71	376.03	904.13
Payable days	--	785.55	549.99	827.66	640.43	603.86
Cash Conversion Cycle	--	-401.52	-180.88	-398.70	-229.91	327.83

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Income Statement ($ Mln)